Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
SANOFI VOLTOOIT HAAR ACQUISITIE VAN ABLYNX NA HET VERSTRIJKEN VAN DE SQUEEZE-OUT PROCEDURE

2018-06-19 globenewswire
PARIJS, Frankrijk en GENT, België - 19 juni 2018 - Sanofi (Euronext: SAN; NYSE: SNY) en Ablynx kondigen vandaag aan dat Sanofi nu alle uitstaande aandelen (met inbegrip van aandelen vertegenwoordigd door American Depositary Shares ("ADSs")), warrants en converteerbare obligaties (samen, de "Effecten") van Ablynx NV ("Ablynx") heeft verworven na het verstrijken van de Squeeze-out procedure.
MKGAF MKGAY ABYLY SNY ABLX ABLYF

0
SANOFI COMPLETES ITS ACQUITISION OF ABLYNX FOLLOWING THE EXPIRATION OF THE SQUEEZE-OUT PROCEDURE

2018-06-19 globenewswire
PARIS, France and GHENT, Belgium - June 19, 2018 - Sanofi (Euronext: SAN; NYSE: SNY) and Ablynx announced today that Sanofi has now acquired all outstanding shares (including shares represented by American Depositary Shares ("ADSs")), warrants and convertible bonds (together, the "Securities") of Ablynx NV ("Ablynx") following the expiration of the Squeeze-out procedure.
MKGAF MKGAY ABYLY SNY ABLX ABLYF

0
ECA2018-104 - Information Regarding the Squeeze-Out and Tender Offer for Ablynx NV (ABLX)

2018-06-11 nasdaqtrader
The squeeze-out period following the expiration of the tender offer by Sanofi to acquire all of the outstanding shares and by representation, the American Depositary Shares of Ablynx NV (ABLX), is expected to be completed on Tuesday, June 12, 2018. If completed, the squeeze-out period will allow for the completion of the acquisition of Ablynx NV on June 12, 2018. The details are as follows:
ABYLY ABLX ABLYF

0
OPENBAARMAKING IN OVEREENSTEMMING MET ARTIKEL 14 VAN DE BELGISCHE WET VAN 2 MEI 2007 BETREFFENDE DE OPENBAARMAKING VAN BELANGRIJKE DEELNEMINGEN (DE "TRANSPARANTIEWET")

2018-05-28 globenewswire
GENT, België, 28 mei 2018 - Ablynx [Euronext Brussels en Nasdaq: ABLX] maakte vandaag bekend, in overeenstemming met artikel 14 van de Belgische wet van 2 mei 2007 betreffende de openbaarmaking van belangrijke deelnemingen in emittenten van wie aandelen zijn toegelaten tot verhandeling op een gereglementeerde markt (de "Transparantiewet"), dat zij op 24 mei 2018 een kennisgeving van deelneming heeft ontvangen van Sanofi S.
MKGAF MKGAY ABYLY ABLX ABLYF

0
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")

2018-05-28 globenewswire
GHENT, Belgium, 28 May 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of shareholdings from Sanofi S.A. on 24 May 2018.
MKGAF MKGAY ABYLY ABLX ABLYF

0
OPENBAARMAKING IN OVEREENSTEMMING MET ARTIKEL 14 VAN DE BELGISCHE WET VAN 2 MEI 2007 BETREFFENDE DE OPENBAARMAKING VAN BELANGRIJKE DEELNEMINGEN (DE "TRANSPARANTIEWET")

2018-05-28 globenewswire
GENT, België, 28 mei 2018 - Ablynx [Euronext Brussels en Nasdaq: ABLX] maakte vandaag bekend, in overeenstemming met artikel 14 van de Belgische wet van 2 mei 2007 betreffende de openbaarmaking van belangrijke deelnemingen in emittenten van wie aandelen zijn toegelaten tot verhandeling op een gereglementeerde markt (de "Transparantiewet"), dat zij kennisgevingen van deelneming heeft ontvangen van Farallon Capital Management, LLC; Marshall Wace LLP; Van Herk Investments B.
MKGAF MKGAY ABYLY ABLX ABLYF

0
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")

2018-05-28 globenewswire
GHENT, Belgium, 28 May 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received notifications of shareholdings from Farallon Capital Management, LLC; Marshall Wace LLP; Van Herk Investments B.
MKGAF MKGAY ABYLY ABLX ABLYF

0
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")

2018-05-21 globenewswire
GHENT, Belgium, 21 May 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of shareholdings from BlackRock, Inc. on 16 May 2018.
MKGAF MKGAY ABYLY ABLX ABLYF

0
OPENBAARMAKING IN OVEREENSTEMMING MET ARTIKEL 14 VAN DE BELGISCHE WET VAN 2 MEI 2007 BETREFFENDE DE OPENBAARMAKING VAN BELANGRIJKE DEELNEMINGEN (DE "TRANSPARANTIEWET")

2018-05-21 globenewswire
GENT, België, 21 mei 2018 - Ablynx [Euronext Brussels en Nasdaq: ABLX] maakte vandaag bekend, in overeenstemming met artikel 14 van de Belgische wet van 2 mei 2007 betreffende de openbaarmaking van belangrijke deelnemingen in emittenten van wie aandelen zijn toegelaten tot verhandeling op een gereglementeerde markt (de "Transparantiewet"), dat zij op 16 mei 2018 een kennisgeving van deelneming heeft ontvangen van BlackRock, Inc.
MKGAF MKGAY ABYLY ABLX ABLYF

0
OPENBAARMAKING IN OVEREENSTEMMING MET ARTIKEL 14 VAN DE BELGISCHE WET VAN 2 MEI 2007 BETREFFENDE DE OPENBAARMAKING VAN BELANGRIJKE DEELNEMINGEN (DE "TRANSPARANTIEWET")

2018-05-11 globenewswire
GENT, België, 11 mei 2018 - Ablynx [Euronext Brussels en Nasdaq: ABLX] maakte vandaag bekend, in overeenstemming met artikel 14 van de Belgische wet van 2 mei 2007 betreffende de openbaarmaking van belangrijke deelnemingen in emittenten van wie aandelen zijn toegelaten tot verhandeling op een gereglementeerde markt (de "Transparantiewet"), dat zij op 8 mei 2018 een kennisgeving van deelneming heeft ontvangen van BlackRock, Inc.
MKGAF MKGAY ABYLY ABLX ABLYF

0
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")

2018-05-11 globenewswire
GHENT, Belgium, 11 May 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of shareholdings from BlackRock, Inc. on 8 May 2018.
MKGAF MKGAY ABYLY ABLX ABLYF

0
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")

2018-05-08 globenewswire
GHENT, Belgium, 8 May 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received two notification of shareholdings from BlackRock, Inc. on 3 and 7 May 2018.
MKGAF MKGAY ABYLY ABLX ABLYF

0
OPENBAARMAKING IN OVEREENSTEMMING MET ARTIKEL 14 VAN DE BELGISCHE WET VAN 2 MEI 2007 BETREFFENDE DE OPENBAARMAKING VAN BELANGRIJKE DEELNEMINGEN (DE "TRANSPARANTIEWET")

2018-05-08 globenewswire
GENT, België, 8 mei 2018 - Ablynx [Euronext Brussels en Nasdaq: ABLX] maakte vandaag bekend, in overeenstemming met artikel 14 van de Belgische wet van 2 mei 2007 betreffende de openbaarmaking van belangrijke deelnemingen in emittenten van wie aandelen zijn toegelaten tot verhandeling op een gereglementeerde markt (de "Transparantiewet"), dat zij op 3 mei 2018 twee kennisgevingen van deelneming heeft ontvangen van BlackRock, Inc.
MKGAF MKGAY ABYLY ABLX ABLYF

2
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")

2018-05-03 globenewswire
GHENT, Belgium, 3 May 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received two notifications of shareholdings from UBS Group AG on 30 April 2018.
MKGAF MKGAY UBS ABYLY ULSGF ABLX ABLYF

2
OPENBAARMAKING IN OVEREENSTEMMING MET ARTIKEL 14 VAN DE BELGISCHE WET VAN 2 MEI 2007 BETREFFENDE DE OPENBAARMAKING VAN BELANGRIJKE DEELNEMINGEN (DE "TRANSPARANTIEWET")

2018-05-03 globenewswire
GENT, België, 3 mei 2018 - Ablynx [Euronext Brussels en Nasdaq: ABLX] maakte vandaag bekend, in overeenstemming met artikel 14 van de Belgische wet van 2 mei 2007 betreffende de openbaarmaking van belangrijke deelnemingen in emittenten van wie aandelen zijn toegelaten tot verhandeling op een gereglementeerde markt (de "Transparantiewet"), dat zij op 30 april 2018 twee kennisgevingen van deelneming heeft ontvangen van UBS Group AG.
MKGAF MKGAY UBS ABYLY ULSGF ABLX ABLYF

Related Articles

BLDP: Ballard Power Systems Analysis and Research Report

2018-08-13 - Asif

Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...

MARA: Marathon Patent Group Analysis and Research Report

2018-08-13 - Asif

Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...

ECYT: Endocyte Analysis and Research Report

2018-08-13 - Asif

Business and Organization Endocyte, Inc. is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer. The Company uses drug conjugation technology to create novel therapeutics and companion imaging agents for personalized targeted therapies. The agents actively target receptors that are over-expressed on diseased cells relative to healthy cells, such as prostate specific membrane antigen (“PSMA”) in prostate cancer. This targeted approach is designed to safely enable the delivery of highly potent drug payloads. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. In September 2017, the Company entered into a Development and License Agreement (the “License Agreement”) with ABX advanced biochemical compounds – Biomedizinische Forschungsreagenzien GmbH (“ABX”), pursuant to which the Company acquired exclusive ...